ARCA biopharma (ABIO) Getting Positive News Coverage, Study Finds
News headlines about ARCA biopharma (NASDAQ:ABIO) have trended positive on Friday, Accern reports. The research group identifies positive and negative press coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. ARCA biopharma earned a news impact score of 0.27 on Accern’s scale. Accern also gave headlines about the biopharmaceutical company an impact score of 46.2976420134951 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
Shares of ARCA biopharma (ABIO) traded up $0.05 during midday trading on Friday, hitting $1.30. The stock had a trading volume of 81,400 shares, compared to its average volume of 86,927. ARCA biopharma has a one year low of $1.05 and a one year high of $3.00.
ARCA biopharma (NASDAQ:ABIO) last announced its earnings results on Thursday, November 9th. The biopharmaceutical company reported ($0.39) earnings per share for the quarter.
TRADEMARK VIOLATION NOTICE: “ARCA biopharma (ABIO) Getting Positive News Coverage, Study Finds” was published by Daily Political and is the property of of Daily Political. If you are reading this piece on another domain, it was copied illegally and republished in violation of US and international trademark and copyright legislation. The legal version of this piece can be read at https://www.dailypolitical.com/2017/12/01/arca-biopharma-abio-getting-positive-news-coverage-study-finds.html.
About ARCA biopharma
ARCA biopharma, Inc (ARCA) is a biopharmaceutical company. The Company is principally focused on developing genetically-targeted therapies for cardiovascular diseases. The Company’s lead product candidate is Gencaro (bucindolol hydrochloride), a beta-blocker and mild vasodilator that the Company is evaluating in a clinical trial for the treatment of atrial fibrillation (AF) in patients with heart failure with reduced left ventricular ejection fraction (HFREF).
Receive News & Ratings for ARCA biopharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ARCA biopharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.